

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

HCC202

RRID:CVCL_2062

Type: Cell Line

Proper Citation

RRID:CVCL_2062

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2062

Proper Citation: RRID:CVCL_2062

Description: Cell line HCC202 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:11314036](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:20215515](#), [PMID:22414580](#), [PMID:22460905](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC202

Synonyms: HCC-202, HCC0202, Hamon Cancer Center 202

Cross References: CLO:CLO_0003649, EFO:EFO_0001176, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2316, BioGRID_ORCS_Cell_line:660, BioSample:SAMN03471302, BioSample:SAMN10988183, cancercellines:CVCL_2062,

Cell_Model_Passport:SIDM00870, Cosmic:687482, Cosmic:904358, Cosmic:1018461, Cosmic:1047702, Cosmic:1136360, Cosmic:1287882, Cosmic:1603209, Cosmic:1935002, Cosmic:1995429, Cosmic:2165008, Cosmic-CLP:1290906, DepMap:ACH-000725, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1290906, GEO:GSM186725, GEO:GSM186726, GEO:GSM344369, GEO:GSM344419, GEO:GSM350515, GEO:GSM783972, GEO:GSM827455, GEO:GSM844089, GEO:GSM847342, GEO:GSM847484, GEO:GSM887047, GEO:GSM888117, GEO:GSM1053699, GEO:GSM1172872, GEO:GSM1172963, GEO:GSM1374510, GEO:GSM1669853, IARC_TP53:28273, KCLB:9S0202, LiGeA:CCLC_133, LINCS_HMS:50214, LINCS_LDP:LCL-1333, PharmacDB:HCC202_487_2019, PRIDE:PXD000309, Progenetix:CVCL_2062, SLKBase:3500, Wikidata:Q54881628

ID: CVCL_2062

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260905T180218+0000

Ratings and Alerts

No rating or validation information has been found for HCC202.

No alerts have been found for HCC202.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Li H, et al. (2025) Rewiring protein function through genetically encoded oxidative chemistry. bioRxiv : the preprint server for biology.

Hosseini A, et al. (2024) Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. Cell reports, 43(2), 113684.

Thomas JD, et al. (2024) Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates. Molecular cancer therapeutics, 23(4), 541.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. *Developmental cell*, 59(5), 579.

Parida PK, et al. (2022) Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. *Cell metabolism*, 34(1), 90.

Brewer WJ, et al. (2022) Macrophage NFATC2 mediates angiogenic signaling during mycobacterial infection. *Cell reports*, 41(11), 111817.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Molecular cell*, 81(4), 708.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Medina CB, et al. (2021) Pannexin 1 channels facilitate communication between T_H17 cells to restrict the severity of airway inflammation. *Immunity*, 54(8), 1715.

Mabe NW, et al. (2020) G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. *Cell reports*, 33(5), 108341.

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.

Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. *Cell chemical biology*, 27(10), 1229.

Koundouros N, et al. (2020) Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. *Cell*, 181(7), 1596.

Harris IS, et al. (2019) Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. *Cell metabolism*, 29(5), 1166.

Feng WW, et al. (2019) CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. *Cell reports*, 29(11), 3405.

Hirukawa A, et al. (2019) Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. *Cell reports*, 29(2), 249.

McMillan EA, et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. *Cell*, 173(4), 864.

Watson SS, et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. *Cell systems*, 6(3), 329.